Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

High-risk smoldering multiple myeloma represents a biologically advanced precursor state in which clonal plasma cells exhibit features associated with progression toward symptomatic myeloma. As researchers continue exploring early-intervention strategies, understanding the basic pathophysiology of plasma cell disorders—and the targets of emerging therapies—is essential for clinical decision-making. The question below reviews a fundamental physiologic concept related to the mechanisms central to disease progression and therapeutic targeting.